TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS

Market News

Global Toxoplasmosis Treatment Drugs Market: Key Developments

On October 26, 2021, National Institute of Allergy and Infectious Diseases (NIAID) announced Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected patients. Patients take pyrimethamine or placebo three times a week. Patients also take leucovorin calcium orally three times weekly. Enrollment occurs over approximately 12 months. All patients are followed on study until a common study close-out date and final analysis of the study. It is anticipated that this common close-out will occur when the mean duration of time on study therapy will be 3 years. Patients receive a loading dose of pyrimethamine or placebo, plus of leucovorin calcium which was effective treatment for toxoplasmosis.

On March 20, 2020, Dr. Reddy’s Laboratories Ltd, a pharmaceutical company announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (FDA). This product is the only AB-rated generic version Daraprim (pyrimethamine) tablets approved by the U.S. FDA. Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.